^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor) +
    Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Med
    Title:

    Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

    Published date:
    08/29/2022
    Excerpt:
    Pyrotinib plus apatinib demonstrated promising antitumor activity and a manageable safety profile in HER2-mutated or HER2-amplified metastatic NSCLC patients.
    DOI:
    https://doi.org/10.1186/s12916-022-02470-6